These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 30295428)

  • 1. Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids.
    Curtis JR; Xie F; Yang S; Bernatsky S; Chen L; Yun H; Winthrop K
    Arthritis Care Res (Hoboken); 2019 Sep; 71(9):1249-1254. PubMed ID: 30295428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study.
    Calabrese LH; Abud-Mendoza C; Lindsey SM; Lee SH; Tatulych S; Takiya L; Iikuni N; Soma K; Luo Z; Fleischmann R
    Arthritis Care Res (Hoboken); 2020 Mar; 72(3):353-359. PubMed ID: 31207152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.
    Winthrop KL; Curtis JR; Lindsey S; Tanaka Y; Yamaoka K; Valdez H; Hirose T; Nduaka CI; Wang L; Mendelsohn AM; Fan H; Chen C; Bananis E
    Arthritis Rheumatol; 2017 Oct; 69(10):1960-1968. PubMed ID: 28845604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis.
    Curtis JR; Xie F; Yun H; Bernatsky S; Winthrop KL
    Ann Rheum Dis; 2016 Oct; 75(10):1843-7. PubMed ID: 27113415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
    Charles-Schoeman C; van der Heijde D; Burmester GR; Nash P; Zerbini CAF; Connell CA; Fan H; Kwok K; Bananis E; Fleischmann R
    J Rheumatol; 2018 Feb; 45(2):177-187. PubMed ID: 29142036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
    Winthrop KL; Melmed GY; Vermeire S; Long MD; Chan G; Pedersen RD; Lawendy N; Thorpe AJ; Nduaka CI; Su C
    Inflamm Bowel Dis; 2018 Sep; 24(10):2258-2265. PubMed ID: 29850873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
    Yamanaka H; Tanaka Y; Takeuchi T; Sugiyama N; Yuasa H; Toyoizumi S; Morishima Y; Hirose T; Zwillich S
    Arthritis Res Ther; 2016 Jan; 18():34. PubMed ID: 26818974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis.
    Winthrop KL; Yamanaka H; Valdez H; Mortensen E; Chew R; Krishnaswami S; Kawabata T; Riese R
    Arthritis Rheumatol; 2014 Oct; 66(10):2675-84. PubMed ID: 24943354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tofacitinib versus methotrexate in rheumatoid arthritis.
    Lee EB; Fleischmann R; Hall S; Wilkinson B; Bradley JD; Gruben D; Koncz T; Krishnaswami S; Wallenstein GV; Zang C; Zwillich SH; van Vollenhoven RF;
    N Engl J Med; 2014 Jun; 370(25):2377-86. PubMed ID: 24941177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis.
    Bechman K; Subesinghe S; Norton S; Atzeni F; Galli M; Cope AP; Winthrop KL; Galloway JB
    Rheumatology (Oxford); 2019 Oct; 58(10):1755-1766. PubMed ID: 30982883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prior herpes zoster occurrence and high-dose corticosteroids increase herpes zoster risk in rheumatoid arthritis patients receiving janus kinase inhibitors in a retrospective and observational study.
    Chen PK; Chang SH; Chen YM; Chen HH; Huang PH; Huang CC; Yeo KJ; Lan JL; Chen DY
    Clin Rheumatol; 2024 Aug; 43(8):2503-2511. PubMed ID: 38954278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of a European-Prevalent Variant near CD83 and an East Asian-Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome-Wide Association Study Meta-Analyses.
    Bing N; Zhou H; Chen X; Hirose T; Kochi Y; Tsuchida Y; Ishigaki K; Sumitomo S; Fujio K; Zhang B; Valdez H; Vincent MS; Martin D; Clark JD
    Arthritis Rheumatol; 2021 Jul; 73(7):1155-1166. PubMed ID: 33455090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data.
    Takeuchi T; Yamanaka H; Yamaoka K; Arai S; Toyoizumi S; DeMasi R; Fukuma Y; Hirose T; Sugiyama N; Zwillich SH; Tanaka Y
    Mod Rheumatol; 2019 Sep; 29(5):756-766. PubMed ID: 30489177
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety of Tofacitinib in the Treatment of Rheumatoid Arthritis in Latin America Compared With the Rest of the World Population.
    Castañeda OM; Romero FJ; Salinas A; Citera G; Mysler E; Rillo O; Radominski SC; Cardiel MH; Jaller JJ; Alvarez-Moreno C; Ponce de Leon D; Castelli G; García EG; Kwok K; Rojo R
    J Clin Rheumatol; 2017 Jun; 23(4):193-199. PubMed ID: 28145906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.
    Fleischmann R; Mease PJ; Schwartzman S; Hwang LJ; Soma K; Connell CA; Takiya L; Bananis E
    Clin Rheumatol; 2017 Jan; 36(1):15-24. PubMed ID: 27734232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial.
    Strand V; Mysler E; Moots RJ; Wallenstein GV; DeMasi R; Gruben D; Soma K; Iikuni N; Smolen JS; Fleischmann R
    RMD Open; 2019; 5(2):e001040. PubMed ID: 31673419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs.
    Pappas DA; Hooper MM; Kremer JM; Reed G; Shan Y; Wenkert D; Greenberg JD; Curtis JR
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1671-8. PubMed ID: 26018115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
    Burmester GR; Blanco R; Charles-Schoeman C; Wollenhaupt J; Zerbini C; Benda B; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Soma K; Bradley J; Mebus C;
    Lancet; 2013 Feb; 381(9865):451-60. PubMed ID: 23294500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses.
    Lomonte ABV; Radominski SC; Marcolino FMD; Brenol CV; Zerbini CAF; García EG; Akylbekova EL; Rojo R; de Leon DP
    Medicine (Baltimore); 2018 Aug; 97(31):e11609. PubMed ID: 30075534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
    Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
    Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.